1,3-Benzodioxolyl-N-ethylpentanamine: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:1,3-Benzodioxolyl-N-ethylpentanamine}} | {{DISPLAYTITLE:1,3-Benzodioxolyl-N-ethylpentanamine}} | ||
== 1,3-Benzodioxolyl-N-ethylpentanamine == | |||
[[File:EBDP.svg|thumb|right|Chemical structure of 1,3-Benzodioxolyl-N-ethylpentanamine]] | |||
1,3-Benzodioxolyl-N-ethylpentanamine | |||
'''1,3-Benzodioxolyl-N-ethylpentanamine''', also known as '''EBDP''', is a synthetic compound belonging to the class of [[substituted cathinones]]. It is structurally related to other psychoactive substances such as [[MDMA]] and [[mephedrone]]. EBDP is known for its stimulant and empathogenic effects, which are similar to those of other compounds in the [[phenethylamine]] and [[amphetamine]] classes. | |||
== | == Chemical Structure and Properties == | ||
EBDP is characterized by the presence of a 1,3-benzodioxole ring, which is a methylenedioxy group attached to a phenyl ring. This structure is similar to that of [[MDMA]], with the primary difference being the length and substitution of the alkyl chain. The chemical formula for EBDP is C<sub>14</sub>H<sub>19</sub>NO<sub>2</sub>. | |||
The compound is typically synthesized in laboratories and is not found naturally. It is often encountered in the form of a white crystalline powder, which can be ingested orally, insufflated, or injected. | |||
== | == Pharmacology == | ||
==Related | EBDP acts primarily as a [[serotonin]] and [[dopamine]] releasing agent, leading to increased levels of these neurotransmitters in the brain. This action is responsible for its stimulant and empathogenic effects. Users report feelings of euphoria, increased sociability, and heightened sensory perception. | ||
The pharmacokinetics of EBDP, including its metabolism and excretion, are not well-documented, but it is believed to be similar to other substituted cathinones. The duration of effects typically lasts several hours, depending on the dose and route of administration. | |||
== Legal Status == | |||
The legal status of EBDP varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. It is often included in legislation targeting [[designer drugs]] and [[novel psychoactive substances]]. | |||
== Health Risks and Safety == | |||
The use of EBDP carries several health risks, including the potential for addiction, cardiovascular issues, and neurotoxicity. Acute adverse effects may include [[tachycardia]], [[hypertension]], [[hyperthermia]], and [[anxiety]]. Chronic use can lead to more severe health problems, including [[psychosis]] and [[depression]]. | |||
Due to the lack of research on EBDP, its long-term effects are not well understood, and users are advised to exercise caution. | |||
== Related Pages == | |||
* [[Substituted cathinones]] | |||
* [[MDMA]] | * [[MDMA]] | ||
* [[ | * [[Mephedrone]] | ||
* [[ | * [[Phenethylamine]] | ||
* [[ | * [[Amphetamine]] | ||
[[Category:Substituted | [[Category:Substituted cathinones]] | ||
[[Category: | [[Category:Designer drugs]] | ||
[[Category:Stimulants]] | |||
Latest revision as of 05:16, 16 February 2025
1,3-Benzodioxolyl-N-ethylpentanamine[edit]
1,3-Benzodioxolyl-N-ethylpentanamine, also known as EBDP, is a synthetic compound belonging to the class of substituted cathinones. It is structurally related to other psychoactive substances such as MDMA and mephedrone. EBDP is known for its stimulant and empathogenic effects, which are similar to those of other compounds in the phenethylamine and amphetamine classes.
Chemical Structure and Properties[edit]
EBDP is characterized by the presence of a 1,3-benzodioxole ring, which is a methylenedioxy group attached to a phenyl ring. This structure is similar to that of MDMA, with the primary difference being the length and substitution of the alkyl chain. The chemical formula for EBDP is C14H19NO2.
The compound is typically synthesized in laboratories and is not found naturally. It is often encountered in the form of a white crystalline powder, which can be ingested orally, insufflated, or injected.
Pharmacology[edit]
EBDP acts primarily as a serotonin and dopamine releasing agent, leading to increased levels of these neurotransmitters in the brain. This action is responsible for its stimulant and empathogenic effects. Users report feelings of euphoria, increased sociability, and heightened sensory perception.
The pharmacokinetics of EBDP, including its metabolism and excretion, are not well-documented, but it is believed to be similar to other substituted cathinones. The duration of effects typically lasts several hours, depending on the dose and route of administration.
Legal Status[edit]
The legal status of EBDP varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. It is often included in legislation targeting designer drugs and novel psychoactive substances.
Health Risks and Safety[edit]
The use of EBDP carries several health risks, including the potential for addiction, cardiovascular issues, and neurotoxicity. Acute adverse effects may include tachycardia, hypertension, hyperthermia, and anxiety. Chronic use can lead to more severe health problems, including psychosis and depression.
Due to the lack of research on EBDP, its long-term effects are not well understood, and users are advised to exercise caution.
